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HNP-1 is an antimicrobial peptide that undergoes proteolytic cleavage to become a mature peptide. This process represents
the mechanism commonly used by the cells to obtain a fully active antimicrobial peptide. In addition, it has been recently
described that HNP-1 is recognized as substrate by the arginine-speciﬁc ADP-ribosyltransferase-1. Arginine-speciﬁc mono-ADP-
ribosylation is an enzyme-catalyzed post-translational modiﬁcation in which NAD+ serves as donor of the ADP-ribose moiety,
which is transferred to the guanidino group of arginines in target proteins. While the arginine carries one positive charge, the
ADP-ribose is negatively charged at the phosphate moieties at physiological pH. Therefore, the attachment of one or more ADP-
riboseunitsresultsinamarkedchangeofcationicity.ADP-ribosylationofHNP-1drasticallyreducesitscytotoxicandantibacterial
activities. While the chemotactic activity of HNP-1 remains unaltered, its ability to induce interleukin-8 production is enhanced.
The arginine 14 of HNP-1 modiﬁed by the ADP-ribose is in some cases processed into ornithine, perhaps representing a diﬀerent
modality in the regulation of HNP-1 activities.
1.Introduction
Antimicrobial host defense peptides (AMPs) are widely
distributedthroughoutallkingdomsoflifeandrepresentone
of the most ancient host defense factors. All of them display
microbicidal activity against a wide spectrum of Gram-
negative and Gram-positive bacteria, fungi, and viruses [1].
T h et w om a i nc l a s s e so fA M P sp r o d u c e db yh u m a n sa r e
represented by defensins and by the single cathelicidin LL-
37, a peptide of 37 amino acids beginning with two leucin
residues (L-L). Moreover, humans produce basic histatins,
which are released in the oral cavity [2], dermicidins from
the skin, and granulysin, which are released by proteolytic
processing in sweat, and in leucocytes, respectively [3, 4].
Defensins are cationic multifunctional arginine-rich pep-
tides with molecular masses ranging from 3.5 to 6kDa,
characterized by three intramolecular disulﬁde bonds. Based
on the connectivity of the six conserved cysteine residues
and sequence homology, human defensins are grouped into
α-a n dβ-defensins. Human neutrophil peptides, HNP-1 to
4, are the major component of the azurophilic granules of
neutrophils while the β-defensins are mainly expressed in
epithelial cells of various tissues and organs [5–7]. HNP-
1 is synthesized as prepropeptide, which is processed via
diﬀerent sequential proteolytical cleavage steps to the ﬁnal
functional peptide of 30 amino-acid. Cleavage is by far the
most studied post-translational modiﬁcation for AMPs and
is also the topic of several excellent reviews [1, 8, 9]. In
this review we summarize the current knowledge regarding
the inﬂuence of ADP-ribosylation on both structure and
function of peptides belonging to the innate immune system
and we describe this post-translational modiﬁcation at the
molecular level. Moreover, we aim to describe the strong
impact that this modiﬁcation exerts on the ability of HNP-12 International Journal of Peptides
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Figure 1: Schematic representation of the enzyme-catalyzed reversible mono-ADP-ribosylation reaction. The diagram shows the enzymatic
transfer of the ADP-ribose portion from NAD to the guanidine group of an arginine target. Nicotinamide, the remaining portion of NAD,
is simultaneously released. The native arginine is restored by the reaction catalyzed by an ADP-ribosylarginine hydrolase that cleaves the
α-glycosidic bond with the release of ADP-ribose.
to kill bacteria but also on the cytotoxicity versus eukaryotic
cells. ADP-ribosylated-HNP-1 are present in the airways of
patients with inﬂammatory-based diseases [10], therefore
thisnoveldiscoveryhasthepotentialtoopenupnewavenues
of investigation with regard to pulmonary inﬂammatory
diseases, which can be translated into tools for therapeutic
applications.
2. Biochemical Characterization of
Mono-ADP-Ribosylation
MonoADP-ribosylationisareversibleenzymaticpost-trans-
lational modiﬁcation, which alters the chemical and func-
tional properties of the modiﬁed proteins [11]. In this
reaction mono-ADP-ribosyltransferases (ARTs) catalyze the
covalent attachment of an ADP-ribose unit from NAD+ to
speciﬁc amino-acid residues with the simultaneous release of
nicotinamide (Figure 1). The ART activity has been initially
described in prokaryotes as one of the main mechanism of
bacterial pathogenesis [12–14]. More recently ﬁve enzymes
(ART1, ART2, ART3, ART4, and ART5) related to mono-
ADP-ribosylating toxins have been identiﬁed in eukaryotes.
Among them only ART1, ART2, and ART5 contain the R-S-
EXEtriadsignaturetypicalofasubfamilyofarginine-speciﬁc
ARTs. These enzymes selectively recognize and modify Arg
as amino-acid acceptor. This signature is absent in the
other two mammalian transfer enzymes ART3 and ART4,
whose activity has not been characterized yet. ARTs are
glycosylphosphatidylinositol (GPI) linked to the membrane
with the catalytic site at the outer surface of cells with
the exception of ART5, which represents a secretory form
of ART [15, 16]. ADP-ribosylation of arginine residues
can inﬂuence the function of target proteins by several
mechanisms. The ADP-ribosylation reaction introduces a
large and bulky group on the target protein, which is ﬁvefold
bigger (540Da) than the average size of the amino-acid.
Therefore, the presence of a single or multiple ADP-ribose
modiﬁcations can considerably inﬂuence the structure and
the size of antimicrobial peptides with an MW ranging
between 3 and 6kDa. The addition of ADP-ribose can
induce a conformational change in the target protein, which
often results in an activating eﬀect or in the creation of
a new docking site for ADP-ribose binding domains in
other proteins [17]. At the same time the presence of
ADP-ribose can also impede the sterical interaction with
molecular partners. In addition, at neutral pH while the
arginine carries one positive charge, the ADP-ribose is
negatively charged at the phosphate moieties. Therefore,
the transfer of one or more negatively charged ADP-ribose
moieties has the potential to considerably reduce the positive
charge of the modiﬁed Arg and overall the cationicity of
antimicrobials.International Journal of Peptides 3
Table 1: Human defensins.
α
DEF1 HUMAN neutrophil defensin 1 ACYCRIPACIAGERRYGTCIYQGRLWAFCC
DEF1 HUMAN neutrophil defensin 2 CYCRIPACIAGERRYGTCIYQGRLWAFCC
DEF3 HUMAN neutrophil defensin 3 DCYCRIPACIAGERRYGTCIYQGRLWAFCC
DEF4 HUMAN neutrophil defensin 4 VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD
DEF5 HUMAN defensin 5 ATCYCRTGRCATRESLSGVCEISGRLYRLCCR
DEF6 HUMAN defensin 6 TCHC-RRSCYSTEYSYGTCTVMGINHRFCCL
β
DEFB1 HUMAN β-defensin 1 DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK
DEFB2 HUMAN β-defensin 2 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP
DEFB3 HUMAN β-defensin 3 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK
DEFB4 HUMAN β-defensin 4 ELDRICGYGTARCRKK-CRSQEYRIGRCPNTYA-CCLRK
180◦ 180◦
Figure 2: Density electrostatic surface map of HNP-1 peptide.
Positive charges conferred by arginine residues are shown in blue;
the negative charge conferred by glutamic acid residue is in red. The
secondary structure of the peptide was taken from PDB database
(3GNY) and the relative density electrostatic surface map was
obtained using PyMOLWin software.
3.Physiological Implicationsof
Post-TranslationalModiﬁcations of HNP-1
The localization of ART1 on the surface of ciliated and
intermediate epithelial cells lining the airways [18] led to the
proposal that potential substrates for ART1-speciﬁc ADP-
ribosylation could be present in the extracellular milieu.
As shown in Table 1, α-a n dβ-defensins are cationic
peptides with a high content of Arg residues which are the
amino-acid target for the ART1 catalyzed ADP-ribosylation.
Azurophilic granules in inﬂammatory cells mainly store
HNP-1 molecules. Since their main function is to defend the
lung against pathogenic microorganisms, they are secreted
at high concentration at the site of inﬂammation in the
airways by neutrophils [19]; therefore, they could represent
an ART1 substrate. In aqueous solution, HNP-1 is arranged
in a dimeric form, where each monomer presents a positive
net charge equal to +3 (Figure 2), conferred by four arginine
residues (Arg5, Arg14, Arg15, and Arg24) and a negative
glutamic acid (Glu13). The last three arginine residues of
HNP-1 are directly involved in membrane perturbation
while Arg5 is involved in the formation of a salt bridge
with Glu13. The positively charged arginine residues provide
an eﬀective means of attracting dimeric HNP-1 peptide to
target membranes facilitating its interaction with negatively
chargedsurfaces,suchasphosphatidylglycerolorcardiolipin
head groups (Figure 3). Previous studies demonstrate that
the replacement of Arg residues by neutral or oppositely
charged amino acids, and modiﬁcation of the amino-acid
sequence leads to dramatic reduction or loss of activity in
bacterial killing not only in HNP-1 peptide but also in other
cationic antimicrobial peptides [20–22]. It has been shown
(Figure 4) that HNP-1 is ADP-ribosylated when assayed in
vitro in the presence of ART1 and NAD+ [23]. The primary
site of modiﬁcation is Arg14, but also Arg24 is shown to
be ADP-ribosylated after a longer incubation time. Interest-
ingly, Arg14 and Arg24, as described previously, are directly
involved in membrane interaction. Arg5, which is involved
in a salt bridge, is not targeted by ART1. Both forms were
isolated from bronchoalveolar lavage (BAL) of volunteer
with history of smoking [10]. The ADP-ribosylation of
selected Arg might well correlate with recent discoveries,
which show that antibacterial activity is strictly dependent
by cationicity [24] and that only selective Arg support
this activity [25]. While ART2 slightly modiﬁes HNP-1,
ART5 is completely inactive on HNP-1 [10] supporting
the evidence of a speciﬁc modiﬁcation since the mouse
ART1 ortholog and ART1 GPI-linked to the skeletal muscle
membrane modiﬁes HNP-1 with the same intensity [10].
The ADP-ribosylated-HNP-1 exhibited a strong reduction of
antimicrobial activity compared to the unmodiﬁed peptide.
Moreover, while the chemotactic activity of the modiﬁed
and unmodiﬁed HNP-1 resulted unaltered, the ability of
HNP-1 to release interleukin-8 (IL-8) from A549 cells was
enhanced by the presence of ADP-ribose linked to Arg14
[23]. This is in line with the idea that the ADP-ribosylated-
HNP-1 is a completely diﬀerent molecule, which possesses
unique biological characteristics that inﬂuence the ability
to recruit neutrophils in the site of inﬂammation through
the release of IL-8 from epithelial cells. This latter is an
important point since mono- and di-ADP-ribosylated forms
of HNP-1 were found in BAL of patients with pulmonary
diseases such as idiopathic pulmonary ﬁbrosis and asthma.
Though the neutrophils in these diseases were recruited in
high number, and HNP-1 and other isoforms were found
in their granules, modiﬁed HNP-1 were not present. This
suggests that HNP-1 have to be released from neutrophils
to be ADP-ribosylated by ART1, which is expressed at the4 International Journal of Peptides
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Figure 3: Schematic structure of the dimeric form of HNP-1
interacting with the cell membrane. Arg residues that confer a
positive net charge to HNP-1 (green) and that are involved to
membrane interaction are highlighted in cyan and blue. Negatively
charged groups of the cell membrane such as phosphatidyl glycerol
or cardiolipin head groups are highlighted in red. Arg14 and Arg24
is the primary and secondary site of ADP-ribosylation, respectively.
The schematic representation was made using Visual Molecular
Dynamics (VMD) software; HNP-1 secondary structure was taken
from PDB database (3GNY) while cell membrane model was
created with VMD tool.
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Figure 4: Schematic diagram of the HNP-1 ADP-ribosylation. The
picture shows that ART1 catalyzes the transfer of an ADP-ribose
unit from NAD to HNP-1 on Arg14 with simultaneous release of
nicotinamide (NAM) in the extracellular space. ART1 is anchored
via a GPI tail to the outer leaﬂet of the cell membrane.
outersurfaceofepithelialcells.HighconcentrationsofHNP-
1 exert cytotoxic eﬀects towards epithelial cells. In airways of
patients with pulmonary diseases the concentration of HNP-
1 produced by epithelial cells and inﬁltrating neutrophils,
is high. Therefore, these cytotoxic eﬀects may well be
physiologically relevant at sites of inﬂammation and could
result in a high local concentration of HNP-1, thus leading
to cytotoxicity. Since electrostatic interactions play a key
role in the interaction with biological membranes, it is
conceivable that modiﬁcations like ADP-ribosylation, which
link a negatively charged ADP-ribose moiety to the Arg14
and Arg24, may reduce the interaction with biological
membranes and consequently the cytotoxicity that HNP-
1 exerts when its concentration is high. Interestingly, the
cytotoxicity of HNP-1 towards epithelial cells is drastically
reduced when the peptide is ADP-ribosylated [23].
4. Ornithinylationand
Phosphorylation of HNP-1
Post-translational modiﬁcations of HNP-1 are not restricted
to the ADP-ribosylation. As shown in Table 1 defensins are
also rich in Tyr, which are the sites, phosphorylated by
tyrosine kinases. Using a novel phosphoproteomic approach
to identify and validate phosphotyrosine sites it has been
shown that the Tyr21 (YGTCIY∗QGR) in HNP-1 and HNP-
3 is phosphorylated in cancer cell lines [26]. Because these
studies represent an early step in the characterization of
the tyrosine kinase signaling in lung cancer, the role that
this modiﬁcation plays in the defensin activities has to be
established. The phosphoryl group is only 80Da with respect
toADP-ribose, butitisinterestingtonotethatinmodelpep-
tide substrate phosphorylation aﬀects ADP-ribosylation in
the nearby arginyl residues [27]. This possible link between
phosphorylation and ADP-ribosylation could be relevant in
the context of HNP-1 in which the Arg14 and the Arg24 are
close to the Tyr21. Another modiﬁcation that seems to occur
in vivo is the generation of the ornithyl-HNP-1 from ADP-
ribosylated-HNP-1 [28]. The guanidino carbon of the ADP-
ribosylated-arginine can undergo nonenzymatic hydrolysis
resulting in the replacement of the ADP-ribosylarginine
by the noncoded amino-acid ornithine (Figure 5). This
modiﬁcation is speciﬁc, since it targets only the ADP-
ribosylated-arginine at position 14. Moreover, it prevents
the modiﬁed Arg to serve as substrate for subsequent ADP-
ribosylation since ornithine is not recognized as substrate by
ART1. BAL of patients with idiopathic pulmonary ﬁbrosis
and asthma other than mono- and di-ADP-ribosylated-
HNP-1 contained HNP-1 ADP-ribosylated at Arg24 with
ornithine replacing Arg in position 14 suggesting a relevance
of this conversion for the innate immunity in the airway
[28]. Interestingly, when 3 of the 4 Arg (not Arg5) were
replaced by ornithine the bactericidal activity was decreased
suggesting that the conversion of arginine with ornithine can
be important in altering HNP-1 activities [24]. Moreover,
the chemical degradation of the ADP-ribosylated-arginine
in ornithine creates a secondary post-translational mod-
iﬁcation that could potentially amplify the ability of the
cell to regulate the biological activities of the HNP-1 and
consequently the immune response in the airways.
5.ProcessingandReversibilityof
the ADP-Ribose Moiety
Like many post-translational modiﬁcations with regulatory
functions, mono-ADP-ribosylation of Arg is a potentially
reversible process that could lead to a complete or partial
removal of the ADP-ribose unit. A full removal of the ADP-
ribose unit from the modiﬁed amino-acid is catalyzed by a
speciﬁc mammal ADP-ribosylarginine hydrolase-1 (ARH1)
[29], which regenerates free Arg for a new ADP-ribosylation
cycle (Figure 5). Since ARH1 is localized in the intracellular
compartment and modiﬁcation of HNP-1 is catalyzed by
the extracellular ART1, the restoration of unmodiﬁed HNP-
1 due to the action of ARH1 is unlikely. In fact at least
one of the two proteins should translocate across theInternational Journal of Peptides 5
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Figure 5:Diﬀerent mechanisms of processing and cleavage of ADP-ribosylated proteins. The complete removal ofthe ADP-ribose,catalyzed
by an ADP-ribosylarginine hydrolase is indicated in red. The picture in blue frame shows the phosphodiesterase-catalyzed cleavage of the
ADP-ribosylated-protein, giving a phosphoribosylated protein. The picture in the green frame represents the nonenzymatic processing of
the ADP-ribosylated protein to the ornithinylated form as described for HNP-1.
membrane. Partial reversal of the ADP-ribose moiety may
result from the action of extracellular phosphodiesterases
that cleave adenosine-5 -monophopshate from ADP-ribose
yielding a ribosyl moiety attached to the target Arg [30].
This modiﬁcation precludes a new ADP-ribosylation of the
target Arg since it leaves attached a phosphoribose molecule
with a negative charge (Figure 5). Phosphodiesterases are
extracellularly expressed and could potentially cleave the
adenosine-5 -monophopshate from the ADP-ribose of the
ADP-ribosylated-HNP-1. These two latter examples of pro-
cessing have not been described for HNP-1 so far.
6. FuturePerspectivesof ADP-Ribosylation
of Antimicrobials
The molecular and functional comprehension of the biolog-
ical activities of AMPs and how these activities are regulated
in vivo could represent a crucial step in understanding
deeply how innate immunity is modulated, since AMPs
are an important defence mechanism against invading
microorganisms. The biochemical characterization of ADP-
ribosylated antimicrobial peptides, including the interaction
with both their molecular targets and biological membranes,
is important to reach this goal. The study of the functional
role of arginine-ADP-ribosylation of antimicrobial peptides
couldrepresentthestartingpointforﬁndingnewtherapeutic
opportunities. Both NMR and crystallography are by far the
mostpotenttoolsininvestigatingtheproteinstructureprop-
erties. Furthermore, improved structure-function prediction
algorithms are another opportunity to develop synthetic
peptide that mimics modiﬁed portions or inhibitors of this
reaction for therapeutic use. Monitoring the ADP ribosy-
lated peptide should be an interesting strategy to identify
biological targets even though, some AMPs are not directly
bactericidal, but exert their eﬀect by immunomodulation
[31]. Recent improved tools that include antibodies speciﬁc
for ADP-ribosylarginine [32] or the possibility to generate
site-speciﬁc ADP-ribosylated peptides [33, 34] will be useful
to study and eventually treat pulmonary inﬂammation,
other lung disorders as well as toxin-mediated diseases.
The replacement with ornithine of the Arg linked with
ADP-ribose could represent an alternative pathway for the
regulationofthebiologicalactivitiesofHNP-1throughpost-
translational modiﬁcation. It could be of interest to evaluate
the eﬀects of these modiﬁcations on HNP-1 functions. Since
AMPs are rich in Arg but also contain amino acids potential
substrate for phosphorylation (Table 1), it could be also of
interesttoevaluatewhethertheregulationofbiologicalactiv-
ities of antimicrobials by ADP-ribosylation or phosphoryla-
tion is restricted to HNP-1 or is a more generic mechanism.
7. Conclusions
In this review we have described how the ADP-ribosylation
of speciﬁc Arg residues of HNP-1 aﬀects its biological
properties. The biological activities of HNP-1 are strictly
dependent on the elevated cationicity due to the presence of
Arg residues. Mono ADP-ribosylation is one example how
post-translational modiﬁcations can aﬀect the functions of
peptides such as the α-defensin. In the era of microarray
technology it has to be recognized that the analysis of
the expression and regulation of single genes alone is not
suﬃcient to understand the functional roles of proteins
and peptides within normal or pathological situations. The
interplay between ADP-ribosylation and phosphorylation,
beyond the analysis of the functional eﬀects that each single
reaction can exerts on peptides belonging to the innate
immunity system, should be also taken into consideration.6 International Journal of Peptides
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